PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28238167-8	2017	Treatment of 3xTg-AD mice with flavocoxid reduced: (1) learning and memory loss; (2) the increased eicosanoid production and the phosphorylation level of amyloid precursor protein (APP-pThr668), Abeta 1-42, p-tau (pThr181), pERK, and the activation of the NLRP3 inflammasome; (3) Abeta plaques; and (4) neuronal loss, compared to saline-treated animals.	flavocoxid	31-41	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	224-228
28238167-8	2017	Treatment of 3xTg-AD mice with flavocoxid reduced: (1) learning and memory loss; (2) the increased eicosanoid production and the phosphorylation level of amyloid precursor protein (APP-pThr668), Abeta 1-42, p-tau (pThr181), pERK, and the activation of the NLRP3 inflammasome; (3) Abeta plaques; and (4) neuronal loss, compared to saline-treated animals.	flavocoxid	31-41	NLR family, pyrin domain containing 3	Mus musculus	256-261
26541818-0	2016	The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.	flavocoxid	61-71	arachidonate 5-lipoxygenase	Homo sapiens	36-50
27450484-8	2016	Flavocoxid, zileuton and celecoxib improved weight loss, reduced colonic myeloperoxydase activity, macroscopic and microscopic damage, and TNF-alpha serum levels.	flavocoxid	0-10	tumor necrosis factor	Rattus norvegicus	139-148
26541818-0	2016	The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation.	flavocoxid	61-71	negative elongation factor complex member C/D	Homo sapiens	112-115
26541818-8	2016	The direct inhibitory effect on Th1/Th17 differentiation, and promoting the development of M2 macrophages and microglia, represent novel mechanisms for the flavocoxid anti-inflammatory activity.	flavocoxid	156-166	negative elongation factor complex member C/D	Homo sapiens	32-35
22471974-14	2012	Flavocoxid-mediated induction of apoptosis was inhibited by the pan-caspase inhibitor, Z-VAD-FMK, in PC3 cells, suggesting an essential role of caspases in flavocoxid-mediated apoptosis during prostatic growth.	flavocoxid	156-166	caspase 9	Homo sapiens	144-152
26424772-3	2015	Flavocoxid is a flavonoid that induces a balanced inhibition of cyclooxygenase (COX)-1 and COX-2 peroxidase moieties and of 5-lipoxygenase (LOX) and has efficacy in the male genitourinary system.	flavocoxid	0-10	cytochrome c oxidase I, mitochondrial	Mus musculus	64-86
26424772-3	2015	Flavocoxid is a flavonoid that induces a balanced inhibition of cyclooxygenase (COX)-1 and COX-2 peroxidase moieties and of 5-lipoxygenase (LOX) and has efficacy in the male genitourinary system.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	91-96
26424772-3	2015	Flavocoxid is a flavonoid that induces a balanced inhibition of cyclooxygenase (COX)-1 and COX-2 peroxidase moieties and of 5-lipoxygenase (LOX) and has efficacy in the male genitourinary system.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Mus musculus	124-138
26424772-3	2015	Flavocoxid is a flavonoid that induces a balanced inhibition of cyclooxygenase (COX)-1 and COX-2 peroxidase moieties and of 5-lipoxygenase (LOX) and has efficacy in the male genitourinary system.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Mus musculus	140-143
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	tumor necrosis factor	Mus musculus	71-80
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	82-87
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Mus musculus	89-94
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	BCL2-associated X protein	Mus musculus	101-104
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	transforming growth factor, beta 3	Mus musculus	115-124
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	B cell leukemia/lymphoma 2	Mus musculus	136-141
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	occludin	Mus musculus	168-176
26424772-10	2015	Flavocoxid administration reduced, in a time-dependent way, p-ERK 1/2, TNF-alpha, COX-2, 5-LOX, MDA, Bax, FSH, LH, TGF-beta3, augmented Bcl-2, testosterone, inhibin B, occludin, N-Cadherin, and improved the structural organization of the testis and the blood-testis barrier.	flavocoxid	0-10	cadherin 2	Mus musculus	178-188
24561313-0	2014	Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Homo sapiens	51-65
26341793-1	2015	Flavocoxid is a mixed extract containing baicalin and catechin, and it acts as a dual balanced inhibitor of cyclooxygenase-1 (COX-1) and COX-2 peroxidase enzyme activities with a significant inhibition of 5-lipoxygenase (5-LOX) enzyme activity in vitro.	flavocoxid	0-10	prostaglandin G/H synthase 1	Oryctolagus cuniculus	108-124
26341793-1	2015	Flavocoxid is a mixed extract containing baicalin and catechin, and it acts as a dual balanced inhibitor of cyclooxygenase-1 (COX-1) and COX-2 peroxidase enzyme activities with a significant inhibition of 5-lipoxygenase (5-LOX) enzyme activity in vitro.	flavocoxid	0-10	prostaglandin G/H synthase 1	Oryctolagus cuniculus	126-131
26341793-11	2015	Rabbits in flavocoxid group showed significantly lower levels of serum CRP, serum, and aortic MDA and higher levels of serum HDL-C, serum, and aortic GSH and SOD compared to HCD group.	flavocoxid	11-21	C-reactive protein	Oryctolagus cuniculus	71-74
22471974-0	2012	Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.	flavocoxid	11-21	arachidonate 5-lipoxygenase	Homo sapiens	51-65
22471974-3	2012	Flavocoxid is a novel flavonoid-based "dual inhibitor" of the COX and 5-LOX enzymes.	flavocoxid	0-10	lysyl oxidase	Homo sapiens	72-75
22471974-11	2012	KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2)  and leukotriene B(4)  (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA.	flavocoxid	13-23	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	97-108
22471974-11	2012	KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2)  and leukotriene B(4)  (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA.	flavocoxid	13-23	lysyl oxidase	Homo sapiens	109-112
22471974-11	2012	KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2)  and leukotriene B(4)  (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA.	flavocoxid	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	216-219
22471974-11	2012	KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2)  and leukotriene B(4)  (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA.	flavocoxid	13-23	caspase 9	Homo sapiens	224-233
22471974-11	2012	KEY RESULTS: Flavocoxid reduced prostate weight and hyperplasia, blunted inducible expression of COX-2 and 5-LOX as well as the increased production of PGE(2)  and leukotriene B(4)  (LTB(4) ), enhanced pro-apoptotic Bax and caspase-9 and decreased the anti-apoptotic Bcl-2 mRNA.	flavocoxid	13-23	BCL2 apoptosis regulator	Homo sapiens	267-272
22471974-12	2012	Flavocoxid also reduced EGF and VEGF expression.	flavocoxid	0-10	vascular endothelial growth factor A	Homo sapiens	32-36
22471974-14	2012	Flavocoxid-mediated induction of apoptosis was inhibited by the pan-caspase inhibitor, Z-VAD-FMK, in PC3 cells, suggesting an essential role of caspases in flavocoxid-mediated apoptosis during prostatic growth.	flavocoxid	0-10	caspase 9	Homo sapiens	144-152
22471974-15	2012	CONCLUSION AND IMPLICATIONS: Our results show that a "dual inhibitor" of the COX and 5-LOX enzymes, such as flavocoxid, might represent a rational approach to reduce BPH through modulation of eicosanoid production and a caspase-induced apoptotic mechanism.	flavocoxid	108-118	lysyl oxidase	Homo sapiens	87-90
21765617-0	2011	Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.	flavocoxid	0-10	phospholipase A2 group IB	Rattus norvegicus	20-36
22356547-0	2012	Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	32-43
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	48-53
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	59-73
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	75-80
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	251-256
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	258-263
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	nitric oxide synthase 2	Rattus norvegicus	268-299
22356547-2	2012	Flavocoxid, a dual inhibitor of cyclooxygenase (COX-2) and 5-lipoxygenase (5-LOX), has been shown in vitro to possess antiinflammatory activity in lipopolysaccharide (LPS)-stimulated rat macrophages by reducing nuclear factor (NF)-kappaB activity and COX-2, 5-LOX and inducible nitric oxide synthase (iNOS) expression.	flavocoxid	0-10	nitric oxide synthase 2	Rattus norvegicus	301-305
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	82-87
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Mus musculus	89-94
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	tumor necrosis factor	Mus musculus	96-105
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	interleukin 6	Mus musculus	110-114
22356547-10	2012	Flavocoxid administration improved survival, reduced the expression of NF-kappaB, COX-2, 5-LOX, TNF-alpha and IL-6 and increased IL-10 production.	flavocoxid	0-10	interleukin 10	Mus musculus	129-134
22356547-11	2012	Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved beta-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-alpha and IL-6, and increased IL-10 and lipoxin A4 serum levels.	flavocoxid	10-20	arrestin, beta 2	Mus musculus	96-111
22356547-11	2012	Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved beta-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-alpha and IL-6, and increased IL-10 and lipoxin A4 serum levels.	flavocoxid	10-20	tumor necrosis factor	Mus musculus	150-159
22356547-11	2012	Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved beta-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-alpha and IL-6, and increased IL-10 and lipoxin A4 serum levels.	flavocoxid	10-20	interleukin 6	Mus musculus	164-168
22356547-11	2012	Moreover, flavocoxid inhibited the mitogen-activated protein kinases (MAPKs) pathway, preserved beta-arrestin 2 expression, reduced blood LTB4, PGE2, TNF-alpha and IL-6, and increased IL-10 and lipoxin A4 serum levels.	flavocoxid	10-20	interleukin 10	Mus musculus	184-189
22356547-12	2012	The treatment with flavocoxid also protected against the histologic damage induced by CLP and reduced the myeloperoxidase (MPO) activity in the lung and liver.	flavocoxid	19-29	myeloperoxidase	Mus musculus	106-121
22356547-12	2012	The treatment with flavocoxid also protected against the histologic damage induced by CLP and reduced the myeloperoxidase (MPO) activity in the lung and liver.	flavocoxid	19-29	myeloperoxidase	Mus musculus	123-126
21765617-0	2011	Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	92-106
21765617-0	2011	Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	117-122
21765617-2	2011	Flavocoxid titrated into rat peritoneal macrophage cultures inhibited cellular phospholipase A2 (PLA(2)) (IC(50) = 60 mug/mL).	flavocoxid	0-10	phospholipase A2 group IB	Rattus norvegicus	79-95
21765617-2	2011	Flavocoxid titrated into rat peritoneal macrophage cultures inhibited cellular phospholipase A2 (PLA(2)) (IC(50) = 60 mug/mL).	flavocoxid	0-10	phospholipase A2 group IB	Rattus norvegicus	97-103
21765617-3	2011	In in vitro enzyme assays, flavocoxid showed little anti-cyclooxygenase (CO) activity on COX-1/-2 enzymes, but inhibited the COX-1 (IC(50) = 12.3) and COX-2 (IC(50) = 11.3 mug/mL) peroxidase (PO) moieties as well as 5-lipoxygenase (5-LOX) (IC(50) = 110 mug/mL).	flavocoxid	27-37	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	125-130
21765617-3	2011	In in vitro enzyme assays, flavocoxid showed little anti-cyclooxygenase (CO) activity on COX-1/-2 enzymes, but inhibited the COX-1 (IC(50) = 12.3) and COX-2 (IC(50) = 11.3 mug/mL) peroxidase (PO) moieties as well as 5-lipoxygenase (5-LOX) (IC(50) = 110 mug/mL).	flavocoxid	27-37	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	151-156
21765617-3	2011	In in vitro enzyme assays, flavocoxid showed little anti-cyclooxygenase (CO) activity on COX-1/-2 enzymes, but inhibited the COX-1 (IC(50) = 12.3) and COX-2 (IC(50) = 11.3 mug/mL) peroxidase (PO) moieties as well as 5-lipoxygenase (5-LOX) (IC(50) = 110 mug/mL).	flavocoxid	27-37	arachidonate 5-lipoxygenase	Rattus norvegicus	216-230
21765617-3	2011	In in vitro enzyme assays, flavocoxid showed little anti-cyclooxygenase (CO) activity on COX-1/-2 enzymes, but inhibited the COX-1 (IC(50) = 12.3) and COX-2 (IC(50) = 11.3 mug/mL) peroxidase (PO) moieties as well as 5-lipoxygenase (5-LOX) (IC(50) = 110 mug/mL).	flavocoxid	27-37	arachidonate 5-lipoxygenase	Rattus norvegicus	232-237
20972845-1	2010	OBJECTIVE: twice-daily flavocoxid, a cyclooxygenase and 5-lipoxygenase inhibitor with potent antioxidant activity of botanical origin, was evaluated for 12 weeks in a randomized, double-blind, active-comparator study against naproxen in 220 subjects with moderate-severe osteoarthritis (OA) of the knee.	flavocoxid	23-33	arachidonate 5-lipoxygenase	Homo sapiens	56-70
20977452-0	2010	Flavocoxid, a dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, reduces pancreatic damage in an experimental model of acute pancreatitis.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Homo sapiens	53-67
20977452-9	2010	In CER-treated animals, but not in those given saline, flavocoxid inhibited COX-2 and 5-LOX expression, reduced serum levels of lipase and amylase and the degree of pancreatic oedema.	flavocoxid	55-65	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	76-87
20977452-9	2010	In CER-treated animals, but not in those given saline, flavocoxid inhibited COX-2 and 5-LOX expression, reduced serum levels of lipase and amylase and the degree of pancreatic oedema.	flavocoxid	55-65	lysyl oxidase	Homo sapiens	88-91
20977452-10	2010	Treatment with flavocoxid blunted the increased pancreatic TNF-alpha mRNA expression, serum leukotriene B4 and prostaglandin E2 levels, and protected against histological damage in terms of vacuolization and leukocyte infiltration.	flavocoxid	15-25	tumor necrosis factor	Homo sapiens	59-68
20845002-1	2010	INTRODUCTION: Flavocoxid is a novel flavonoid-based "dual inhibitor" of the 5-lipoxygenase (5-LOX) enzyme and the cyclooxygenase (COX) enzymes.	flavocoxid	14-24	arachidonate 5-lipoxygenase	Homo sapiens	76-90
20845002-1	2010	INTRODUCTION: Flavocoxid is a novel flavonoid-based "dual inhibitor" of the 5-lipoxygenase (5-LOX) enzyme and the cyclooxygenase (COX) enzymes.	flavocoxid	14-24	arachidonate 5-lipoxygenase	Homo sapiens	92-97
20845002-9	2010	CONCLUSION: Flavocoxid, a first-in-class flavonoid-based therapeutic that inhibits COX-1 and COX-2 as well as 5-LOX, was as effective as naproxen in managing the signs and symptoms of OA of the knee.	flavocoxid	12-22	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	83-88
20845002-9	2010	CONCLUSION: Flavocoxid, a first-in-class flavonoid-based therapeutic that inhibits COX-1 and COX-2 as well as 5-LOX, was as effective as naproxen in managing the signs and symptoms of OA of the knee.	flavocoxid	12-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	93-98
20845002-9	2010	CONCLUSION: Flavocoxid, a first-in-class flavonoid-based therapeutic that inhibits COX-1 and COX-2 as well as 5-LOX, was as effective as naproxen in managing the signs and symptoms of OA of the knee.	flavocoxid	12-22	arachidonate 5-lipoxygenase	Homo sapiens	110-115
20556559-1	2010	INTRODUCTION: Flavocoxid, a botanical, anti-inflammatory agent, nonspecifically inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	14-24	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	132-137
20556559-1	2010	INTRODUCTION: Flavocoxid, a botanical, anti-inflammatory agent, nonspecifically inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	14-24	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	142-147
19555810-8	2009	In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors.	flavocoxid	32-42	prostaglandin-endoperoxide synthase 2	Homo sapiens	251-267
19681869-13	2009	Finally, flavocoxid decreased MDA, TNF and nitrite levels from LPS-stimulated macrophages.	flavocoxid	9-19	tumor necrosis factor	Rattus norvegicus	35-38
19786019-4	2009	We evaluated whether flavocoxid, a mixed flavonoid extract with anti-inflammatory, antioxidant and NF-kappaB inhibiting properties, has beneficial effects in mdx mice in comparison with methylprednisolone, the gold standard treatment for DMD patients.	flavocoxid	21-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
19786019-10	2009	The administration of flavocoxid: (1) ameliorated functional properties in vivo and ex vivo; (2) reduced CK; (3) reduced the expression of oxidative stress markers and of inflammatory mediators; (4) inhibited NF-kappaB and mitogen-activated protein kinases (MAPKs) signal pathways; (5) reduced muscle necrosis and enhanced regeneration.	flavocoxid	22-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	209-218
19786019-11	2009	Our results highlight the detrimental effects of oxidative stress and NF-kappaB, MAPKs and COX/5-LOX pathways in the dystrophic process and show that flavocoxid is more effective in mdx mice than methylprednisolone.	flavocoxid	150-160	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	70-79
19786019-11	2009	Our results highlight the detrimental effects of oxidative stress and NF-kappaB, MAPKs and COX/5-LOX pathways in the dystrophic process and show that flavocoxid is more effective in mdx mice than methylprednisolone.	flavocoxid	150-160	arachidonate 5-lipoxygenase	Mus musculus	95-100
19681869-0	2009	Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	51-65
19681869-2	2009	Flavocoxid is a mixed extract containing baicalin and catechin, and acts as a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (LOX) enzymes.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	121-135
19681869-2	2009	Flavocoxid is a mixed extract containing baicalin and catechin, and acts as a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (LOX) enzymes.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	137-140
19681869-10	2009	Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression.	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	55-60
19681869-10	2009	Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	130-133
19681869-10	2009	Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression.	flavocoxid	0-10	nitric oxide synthase 2	Rattus norvegicus	204-208
19681869-10	2009	Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression.	flavocoxid	0-10	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	306-311
19681869-10	2009	Flavocoxid (128 microg.mL(-1)) significantly inhibited COX-2 (LPS = 18 +/- 2.1; flavocoxid = 3.8 +/- 0.9 integrated intensity), 5-LOX (LPS = 20 +/- 3.8; flavocoxid = 3.1 +/- 0.8 integrated intensity) and iNOS expression (LPS = 15 +/- 1.1; flavocoxid = 4.1 +/- 0.4 integrated intensity), but did not modify COX-1 expression.	flavocoxid	80-90	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	55-60
19681869-12	2009	Flavocoxid also prevented the loss of IkappaB-alpha protein (LPS = 1.9 +/- 0.2; flavocoxid = 7.2 +/- 1.6 integrated intensity), blunted increased NF-kappaB binding activity (LPS = 9.2 +/- 2; flavocoxid = 2.4 +/- 0.7 integrated intensity) and the enhanced TNF-alpha mRNA levels (LPS = 8 +/- 0.9; flavocoxid = 1.9 +/- 0.8 n-fold/beta-actin) induced by LPS.	flavocoxid	0-10	NFKB inhibitor alpha	Rattus norvegicus	38-51
19681869-12	2009	Flavocoxid also prevented the loss of IkappaB-alpha protein (LPS = 1.9 +/- 0.2; flavocoxid = 7.2 +/- 1.6 integrated intensity), blunted increased NF-kappaB binding activity (LPS = 9.2 +/- 2; flavocoxid = 2.4 +/- 0.7 integrated intensity) and the enhanced TNF-alpha mRNA levels (LPS = 8 +/- 0.9; flavocoxid = 1.9 +/- 0.8 n-fold/beta-actin) induced by LPS.	flavocoxid	0-10	tumor necrosis factor	Rattus norvegicus	255-264
19681869-12	2009	Flavocoxid also prevented the loss of IkappaB-alpha protein (LPS = 1.9 +/- 0.2; flavocoxid = 7.2 +/- 1.6 integrated intensity), blunted increased NF-kappaB binding activity (LPS = 9.2 +/- 2; flavocoxid = 2.4 +/- 0.7 integrated intensity) and the enhanced TNF-alpha mRNA levels (LPS = 8 +/- 0.9; flavocoxid = 1.9 +/- 0.8 n-fold/beta-actin) induced by LPS.	flavocoxid	0-10	actin, beta	Rattus norvegicus	327-337
34431056-2	2022	The present investigation was undertaken to evaluate the potential protective effect of flavocoxid, a dual COX and LOX inhibitor, in colitis model in rats.	flavocoxid	88-98	lysyl oxidase	Rattus norvegicus	115-118
34906776-3	2022	Flavocoxid is a mixed extract containing baicalin and catechin showing antioxidant effects and anti-inflammatory activity mainly due to a dual inhibition of inducible cyclooxygenase (COX-2), 5-lipoxygenase (5-LOX) and NLRP3 pathway.	flavocoxid	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	183-188
34906776-3	2022	Flavocoxid is a mixed extract containing baicalin and catechin showing antioxidant effects and anti-inflammatory activity mainly due to a dual inhibition of inducible cyclooxygenase (COX-2), 5-lipoxygenase (5-LOX) and NLRP3 pathway.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Homo sapiens	191-205
34906776-3	2022	Flavocoxid is a mixed extract containing baicalin and catechin showing antioxidant effects and anti-inflammatory activity mainly due to a dual inhibition of inducible cyclooxygenase (COX-2), 5-lipoxygenase (5-LOX) and NLRP3 pathway.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Homo sapiens	207-212
34906776-3	2022	Flavocoxid is a mixed extract containing baicalin and catechin showing antioxidant effects and anti-inflammatory activity mainly due to a dual inhibition of inducible cyclooxygenase (COX-2), 5-lipoxygenase (5-LOX) and NLRP3 pathway.	flavocoxid	0-10	NLR family pyrin domain containing 3	Homo sapiens	218-223
34906776-6	2022	Flavocoxid increased Nrf2, prompted a marked reduction in malondialdehyde levels and reduced the expression of COX-2 and 5-LOX together with PGE2, and LTB4 levels.	flavocoxid	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
34906776-6	2022	Flavocoxid increased Nrf2, prompted a marked reduction in malondialdehyde levels and reduced the expression of COX-2 and 5-LOX together with PGE2, and LTB4 levels.	flavocoxid	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	111-116
34906776-6	2022	Flavocoxid increased Nrf2, prompted a marked reduction in malondialdehyde levels and reduced the expression of COX-2 and 5-LOX together with PGE2, and LTB4 levels.	flavocoxid	0-10	arachidonate 5-lipoxygenase	Homo sapiens	121-126
34906776-8	2022	These results suggest a correlation between oxidative stress and NLRP3 activation and indicate that flavocoxid suppresses the inflammatory storm that accompanies oral mucositis.	flavocoxid	100-110	NLR family pyrin domain containing 3	Homo sapiens	65-70
33467104-1	2021	Flavocoxid is a blended extract containing baicalin and catechin with potent antioxidant and anti-inflammatory properties due to the inhibition of the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) enzymes, nuclear factor-kappaB (NF-kappaB), tumor necrosis factor (TNF)-alpha, and the mitogen-activated protein kinases (MAPKs) pathways.	flavocoxid	0-10	tumor necrosis factor	Homo sapiens	243-276
34309798-0	2021	Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-alpha, IL-1beta, iNOS, and Osteogenic Runx2.	flavocoxid	0-10	tumor necrosis factor	Rattus norvegicus	110-119
34309798-0	2021	Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-alpha, IL-1beta, iNOS, and Osteogenic Runx2.	flavocoxid	0-10	interleukin 1 alpha	Rattus norvegicus	121-129
34309798-0	2021	Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-alpha, IL-1beta, iNOS, and Osteogenic Runx2.	flavocoxid	0-10	nitric oxide synthase 2	Rattus norvegicus	131-135
34309798-0	2021	Flavocoxid Ameliorates Aortic Calcification Induced by Hypervitaminosis D3 and Nicotine in Rats Via Targeting TNF-alpha, IL-1beta, iNOS, and Osteogenic Runx2.	flavocoxid	0-10	RUNX family transcription factor 2	Rattus norvegicus	152-157
34309798-8	2021	RESULTS: Compared to untreated VC rats, FCX treatment prevented body weight loss, reduced aortic calcium deposition, restored normal values of SBP, DBP, and HR, and attenuated LV hypertrophy.	flavocoxid	40-43	spermine binding protein	Rattus norvegicus	143-146
34309798-8	2021	RESULTS: Compared to untreated VC rats, FCX treatment prevented body weight loss, reduced aortic calcium deposition, restored normal values of SBP, DBP, and HR, and attenuated LV hypertrophy.	flavocoxid	40-43	D-box binding PAR bZIP transcription factor	Rattus norvegicus	148-151
34309798-9	2021	FCX also improved renal function and ameliorated serum levels of phosphorus, calcium, and ALP in rats with VC.	flavocoxid	0-3	PDZ and LIM domain 3	Rattus norvegicus	90-93
35576032-0	2022	Ameliorative effect of flavocoxid on cyclophosphamide-induced cardio and neurotoxicity via targeting the GM-CSF/NF-kappaB signaling pathway.	flavocoxid	23-33	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	105-111
35576032-0	2022	Ameliorative effect of flavocoxid on cyclophosphamide-induced cardio and neurotoxicity via targeting the GM-CSF/NF-kappaB signaling pathway.	flavocoxid	23-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	112-121
35576032-4	2022	Flavocoxid (Flavo) is a potent antioxidant and anti-inflammatory agent that inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	0-10	cytochrome c oxidase I, mitochondrial	Mus musculus	128-133
35576032-4	2022	Flavocoxid (Flavo) is a potent antioxidant and anti-inflammatory agent that inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	138-143
35576032-4	2022	Flavocoxid (Flavo) is a potent antioxidant and anti-inflammatory agent that inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	12-17	cytochrome c oxidase I, mitochondrial	Mus musculus	128-133
35576032-4	2022	Flavocoxid (Flavo) is a potent antioxidant and anti-inflammatory agent that inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX).	flavocoxid	12-17	cytochrome c oxidase II, mitochondrial	Mus musculus	138-143
35576032-8	2022	Flavo modulated oxidative stress biomarkers (malonaldehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD)), tumor necrosis factor-alpha (TNF-alpha), and interleukin (IL)-1beta.	flavocoxid	0-5	tumor necrosis factor	Mus musculus	147-156
35576032-8	2022	Flavo modulated oxidative stress biomarkers (malonaldehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD)), tumor necrosis factor-alpha (TNF-alpha), and interleukin (IL)-1beta.	flavocoxid	0-5	interleukin 1 alpha	Mus musculus	163-185
35576032-9	2022	Additionally, cardiac troponin I (cTn-I), nuclear factor kappa B (NF-kappaB), brain amyloid precursor protein (APP), and granulocyte macrophage colony-stimulating factor (GM-CSF) were decreased by Flavo administration.	flavocoxid	197-202	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	121-169
35576032-10	2022	Moreover, Flavo ameliorated heart and brain histopathological changes and caspase-3 levels.	flavocoxid	10-15	caspase 3	Mus musculus	74-83
35576032-11	2022	Collectively, Flavo (20 mg/kg) for 14 days showed significant cardio and neuroprotective effects due to its antioxidant, anti-inflammatory, and antiapoptotic activities via modulation of oxidative stress, inflammation, and the GM-CSF/NF-kappaB signaling pathway.	flavocoxid	14-19	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	227-233
35576032-11	2022	Collectively, Flavo (20 mg/kg) for 14 days showed significant cardio and neuroprotective effects due to its antioxidant, anti-inflammatory, and antiapoptotic activities via modulation of oxidative stress, inflammation, and the GM-CSF/NF-kappaB signaling pathway.	flavocoxid	14-19	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	234-243
33467104-5	2021	Flavocoxid induced a significant reduction in serum interleukin (IL)-1 beta and TNF-alpha only in the group of DMD boys on add-on therapy (flavocoxid added to steroids for at least six months).	flavocoxid	0-10	interleukin 1 alpha	Homo sapiens	52-75
33467104-5	2021	Flavocoxid induced a significant reduction in serum interleukin (IL)-1 beta and TNF-alpha only in the group of DMD boys on add-on therapy (flavocoxid added to steroids for at least six months).	flavocoxid	0-10	tumor necrosis factor	Homo sapiens	80-89
29986831-0	2018	Flavocoxid attenuates airway inflammation in ovalbumin-induced mouse asthma model.	flavocoxid	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	45-54
31798452-10	2019	Curcumin, flavocoxid and beta-caryophyllene suppressed IL-1beta expression with different IC50.	flavocoxid	10-20	interleukin 1 alpha	Homo sapiens	55-63
29986831-2	2018	This study provides evidence on the efficacy of flavocoxid against ovalbumin (OVA)-induced allergic airways inflammation in a mouse model of asthma.	flavocoxid	48-58	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	67-76
29986831-11	2018	Collectively, these results demonstrate that flavocoxid mitigates the allergic airway inflammation induced by ovalbumin through attenuation of IL-13, NO expressions and oxidative stress.	flavocoxid	45-55	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	110-119
29986831-11	2018	Collectively, these results demonstrate that flavocoxid mitigates the allergic airway inflammation induced by ovalbumin through attenuation of IL-13, NO expressions and oxidative stress.	flavocoxid	45-55	interleukin 13	Mus musculus	143-148
29849925-10	2018	After 14 days of treatment, flavocoxid administration reduced urea nitrogen and creatinine, iNOS, MMP-9, and pERK 1/2 expression and protein carbonyl; increased GSH, GR, and GPx; and showed an evident preservation of the glomerular and tubular structure and ultrastructure.	flavocoxid	28-38	nitric oxide synthase 2, inducible	Mus musculus	92-96
29849925-10	2018	After 14 days of treatment, flavocoxid administration reduced urea nitrogen and creatinine, iNOS, MMP-9, and pERK 1/2 expression and protein carbonyl; increased GSH, GR, and GPx; and showed an evident preservation of the glomerular and tubular structure and ultrastructure.	flavocoxid	28-38	matrix metallopeptidase 9	Mus musculus	98-103
29849925-10	2018	After 14 days of treatment, flavocoxid administration reduced urea nitrogen and creatinine, iNOS, MMP-9, and pERK 1/2 expression and protein carbonyl; increased GSH, GR, and GPx; and showed an evident preservation of the glomerular and tubular structure and ultrastructure.	flavocoxid	28-38	peroxiredoxin 6 pseudogene 2	Mus musculus	174-177